Monitor whether Affinity Asset Advisors converts this passive 13G to an active 13D, which would signal a shift in intent. The warrant-based position and beneficial ownership limitation suggest a structured investment rather than open-market accumulation.
KPTI drugs
KPTI drug pipeline →Price Chart
How similar events traded
Executive Summary
Affinity Asset Advisors and Michael Cho filed an amended Schedule 13G disclosing a new passive stake of 1,573,517 shares (6.5%) of Karyopharm Therapeutics as of September 30, 2026, all held via warrants subject to a 9.99% beneficial ownership limitation. This is a new filer for this issuer; the stake is passive and the impact is neutral given the small market cap and warrant-based position.
Key Financial Metrics
Key Facts
- Affinity Asset Advisors and Michael Cho report beneficial ownership of 1,573,517 shares (6.5%) as of September 30, 2026
- All shares are issuable upon exercise of warrants, subject to a 9.99% beneficial ownership limitation
- This is a new filing by Affinity Asset Advisors; no prior 13G/A on file for this issuer
- The percentage is based on 24,254,977 shares outstanding (including the warrant shares)
- The filing is passive under Rule 13d-1(b); the filer certifies no intent to change or influence control
Financial Impact
Stake of 1,573,517 shares valued at approximately $65,000 based on market cap of $1M and 24.3M shares outstanding
Risk Factors
- Warrant exercise could increase dilution if the beneficial ownership limitation is waived or adjusted
- The company's tiny $1M market cap makes any large holder's actions potentially impactful on liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001011438-26-000695 |
| Document: 0001011438-26-000695-index.html | 0001011438-26-000695 |
| Document: 0001011438-26-000695.txt | 0001011438-26-000695 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers